The estimated Net Worth of Stephen S. Dominy is at least 2.87 百万$ dollars as of 12 November 2021. Mr. Dominy owns over 763 units of Cortexyme Inc stock worth over 2,373,318$ and over the last 5 years he sold CRTX stock worth over 0$. In addition, he makes 497,344$ as Co-Founder、 Chief Scientific Officer、 Director at Cortexyme Inc.
Stephen has made over 1 trades of the Cortexyme Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 763 units of CRTX stock worth 10,987$ on 12 November 2021.
The largest trade he's ever made was buying 763 units of Cortexyme Inc stock on 12 November 2021 worth over 10,987$. On average, Stephen trades about 191 units every 0 days since 2020. As of 12 November 2021 he still owns at least 1,217,086 units of Cortexyme Inc stock.
You can see the complete history of Mr. Dominy stock trades at the bottom of the page.
Stephen S. Dominy M.D. serves as Co-Founder, Chief Scientific Officer, Director of the Company. Dr. Dominy has served as a member of our board of directors since December 2015 and as our Chief Scientific Officer since April 2016. Prior to co-founding Cortexyme, Dr. Dominy served as a Division Director at San Francisco General Hospital and as Associate Professor of Psychiatry at the University of California, San Francisco School of Medicine from 2006 to 2016. Dr. Dominy holds a B.S. in Pharmacy from The Ohio State University College of Pharmacy and an M.D. from the Wright State University Boonshoft School of Medicine. Dominy is qualified to serve as a director because of his educational background, as well as his extensive research and technical experience that provides an important perspective on operations and development.
As the Co-Founder、 Chief Scientific Officer、 Director of Cortexyme Inc, the total compensation of Stephen Dominy at Cortexyme Inc is 497,344$. There are 9 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of 1,100,170$.
Stephen Dominy is 64, he's been the Co-Founder、 Chief Scientific Officer、 Director of Cortexyme Inc since 2016. There are 2 older and 16 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Stephen's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over 59,595,534$ worth of Cortexyme Inc stock and bought 19,273,711 units worth 164,053,955$ . The most active insiders traders include & Johnson Johnson & Johnson...、Farmaceutici Sp A Chiesi、Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of 475,426$. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth 30,888$.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: